<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337970</url>
  </required_header>
  <id_info>
    <org_study_id>20-001</org_study_id>
    <nct_id>NCT04337970</nct_id>
  </id_info>
  <brief_title>Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer</brief_title>
  <official_title>A Phase Ib/II Study of Talazoparib and Axitinib in Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are doing this study to find out if the combination of the drugs axitinib and&#xD;
      talazoparib is a safe and effective treatment for people with your previously treated&#xD;
      advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes&#xD;
      few or mild side effects when given in combination with a standard dose of axitinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Recommended dose of talazoparib in combination with standard-dose axitinib</measure>
    <time_frame>2 years</time_frame>
    <description>Identify the recommended dose of talazoparib in combination with standard-dose axitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Dose Limiting Toxicity</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-limiting toxicity based on adverse events classified according to CTCAE v5.0 observed over 1 cycle of combination talazoparib and axitinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Objective Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the efficacy as measured by objective response rate (ORR) of combination talazoparib and axitinib in previously treated metastatic clear cell RCC patients.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Unresectable Renal Cell Carcinoma</condition>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase Ib, Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib, Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib, Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II, Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily&#xD;
Phase II: MTD to be determined.</description>
    <arm_group_label>Phase II, Dose Expansion</arm_group_label>
    <arm_group_label>Phase Ib, Dose Level 1</arm_group_label>
    <arm_group_label>Phase Ib, Dose Level 2</arm_group_label>
    <arm_group_label>Phase Ib, Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>5 mg PO BID</description>
    <arm_group_label>Phase II, Dose Expansion</arm_group_label>
    <arm_group_label>Phase Ib, Dose Level 1</arm_group_label>
    <arm_group_label>Phase Ib, Dose Level 2</arm_group_label>
    <arm_group_label>Phase Ib, Dose Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven metastatic or unresectable renal cell carcinoma with clear cell&#xD;
             component&#xD;
&#xD;
          -  Prior treatment with at least 1 VEGFR TKI and 1 PD-1/PD-L1 immune checkpoint inhibitor&#xD;
             (ICI).Combination VEGFR TKI plus ICI will be counted as 1 line of therapy. During the&#xD;
             dose escalation portion of the study prior TKI exposure is not required.&#xD;
&#xD;
          -  Dose escalation portion: No maximum prior lines of therapy. Dose expansion portion:&#xD;
             maximum of two prior lines of therapy&#xD;
&#xD;
          -  Adequate Hematologic Function&#xD;
&#xD;
               -  Absolute Neutrophil Count ≥ 1.5 x 109 / L&#xD;
&#xD;
               -  Platelet Count ≥ 100 x 10^9 / L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  No transfusion of packed red blood cells or platelets within 21 days of Cycle 1&#xD;
                  Day 1&#xD;
&#xD;
          -  Adequate Renal Function ≥ 60 ml/min according to the Cockcroft-Gault formula&#xD;
&#xD;
             ° Patients with moderate renal impairment (creatinine clearance 30-59 ml/min by&#xD;
             Cockcroft-Gault) may be eligible in the phase II dose expansion&#xD;
&#xD;
          -  Adequate Hepatic Function including:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  AST ≤ 3 x upper limit of normal (ULN) without liver metastasis&#xD;
&#xD;
               -  ALT ≤ 3 x upper limit of normal (ULN) without liver metastasis&#xD;
&#xD;
               -  AST or ALT ≤ 5 x upper limit of normal (ULN) for patients with liver metastasis&#xD;
&#xD;
               -  Patients with known Gilbert's syndrome may be included if total bilirubin ≤ x 3&#xD;
                  ULN&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) Performance Status 0-2.&#xD;
&#xD;
          -  Patients must have measurable disease by RECIST v1.1. At least one measurable lesion&#xD;
             should not have been previously irradiated.&#xD;
&#xD;
          -  Women of childbearing potential must have negative urine or serum pregnancy testing at&#xD;
             screening. All women will be considered childbearing potential unless meeting criteria&#xD;
             including:&#xD;
&#xD;
               -  Achieved post-menopausal status as defined by cessation of regular menses for at&#xD;
                  least 12 consecutive months with no alternative pathological or physiological&#xD;
                  cause and have follicular stimulation hormone showing postmenopausal state. Women&#xD;
                  who have been amenorrhoeic for ≥ 12 months are still considered to be of&#xD;
                  childbearing potential if the amenorrhea is possibly due to prior chemotherapy,&#xD;
                  anorexia, low body weight, ovarian suppression, anti-estrogen therapy or other&#xD;
                  medically inducible reasons.&#xD;
&#xD;
               -  Documented hysterectomy or bilateral oophorectomy surgery&#xD;
&#xD;
               -  Medically confirmed ovarian failure&#xD;
&#xD;
               -  Sexually active participants and their partners must agree to use medically&#xD;
                  accepted methods of contraception (i.e. barrier methods including condoms, female&#xD;
                  condom, or diaphragm with spermicidal gel) during the study and for 7 months&#xD;
                  after the last dose of the study treatment for women, and 4 months for men.&#xD;
&#xD;
          -  Recovery of baseline CTCAE v5.0 grade ≤1 toxicities related to prior study treatments&#xD;
             unless adverse events are clinically non-significant per investigator's discretion&#xD;
             and/or stable on supportive therapy if needed.&#xD;
&#xD;
          -  Patients must be willing and able to comply with trial protocol. This includes&#xD;
             adhering to the treatment plan, scheduled visits, laboratory and other study&#xD;
             procedures.&#xD;
&#xD;
        Participant Inclusion Criteria for Phase II Dose Expansion&#xD;
&#xD;
          -  Maximum 2 lines of prior therapy. Combination VEGFR TKI plus ICI therapy will be&#xD;
             accepted as 1 line of therapy.&#xD;
&#xD;
          -  Adequate Renal Function ≥ 30 ml/min according to the Cockcroft-Gault formula.&#xD;
&#xD;
               -  Patients with normal renal function (Cr clearance ≥ 60 ml/min by Cockcroft-Gault&#xD;
                  formula) will receive talazoparib at RP2D.&#xD;
&#xD;
               -  Patients with moderate renal impairment (Cr clearance 30-59 ml/min by&#xD;
                  Cockcroft-Gault formula) will receive talazoparib at one dose level lower than&#xD;
                  RP2D.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with talazoparib or other agents which target PARP&#xD;
&#xD;
          -  Prior treatment with axitinib. Other VEGFR TKIs are permissible.&#xD;
&#xD;
          -  Patients &lt; 18 years old&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding. Fertile patients who are unwilling or&#xD;
             unable to use two methods of contraception (at least one of which considered highly&#xD;
             effective) for duration of study and after study (7 months after last dose of the&#xD;
             study treatment for women, and 4 months for men)&#xD;
&#xD;
          -  Prior diagnosis of myelodysplastic syndrome (MDS) or diagnosis of other malignancy&#xD;
             that requires anti-cancer directed therapy within the last 12 months. Exclusions&#xD;
             include those cancers that are considered cured by local therapy (e.g. basal cell&#xD;
             carcinoma, squamous cell carcinoma, ducal carcinoma in situ of breast, bladder of&#xD;
             cervix) or other cancers that have low malignant potential and do not require systemic&#xD;
             therapy (i.e. Gleason-grade &lt;6 prostate adenocarcinoma, borderline ovarian malignancy&#xD;
             / low malignant potential).&#xD;
&#xD;
          -  Treatment with anti-cancer therapies within 21 days or five half-lives, whichever&#xD;
             shorter, of start date, including monoclonal antibody, cytotoxic therapy, or another&#xD;
             investigational agent.&#xD;
&#xD;
          -  Significant vascular disease (i.e. aortic aneurysm requiring surgical repair, recent&#xD;
             arterial thrombosis) within 6 months prior to first dose of therapy.&#xD;
&#xD;
          -  Ejection Fraction (EF) ≤50% by echocardiogram (ECHO). Multi-gated acquisition scan&#xD;
             (MUGA) should be obtained to estimate EF if quality of ECHO is insufficient.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure (BP) ≥160 mmHg or&#xD;
             diastolic BP ≥ 100 mmHg despite anti-HTN therapy.&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant unexplained coagulopathy (i.e. absent of&#xD;
             anticoagulation)&#xD;
&#xD;
          -  Clinical signs or symptoms of gastrointestinal obstruction requirement parenteral&#xD;
             hydration, parenteral nutrition, or feeding tube.&#xD;
&#xD;
          -  Uncontrolled effusion management (pleural effusion, pericardial effusion, or ascites)&#xD;
             which requires recurrent drainage procedures.&#xD;
&#xD;
          -  Active infection requiring parenteral antibiotic therapy.&#xD;
&#xD;
          -  History of either positive HCV RNA viral load or anti-HCV antibody screening&#xD;
             detectable; HBV infection with HBV surface antigen detection and/or positive HBV DNA&#xD;
             viral load.&#xD;
&#xD;
          -  Known hypersensitivity to talazoparib or axitinib, or any component in formulations.&#xD;
&#xD;
          -  Severe acute or chronic medical conditions which may significantly increase the risk&#xD;
             of study participants, per treating investigator's discretion.&#xD;
&#xD;
          -  Radiation therapy to any site (including bone) &lt;2 weeks prior to the first dose of&#xD;
             therapy&#xD;
&#xD;
          -  Symptomatic brain metastasis or leptomeningeal disease requiring steroid use. Patients&#xD;
             are eligible if they are neurologically stable for 4 weeks, have completed radiation&#xD;
             therapy or surgery, and recovered from side effects. Patients must have discontinued&#xD;
             steroid therapy for at least 2 weeks prior to first dose of study treatment.&#xD;
&#xD;
          -  Current or anticipated use of potent P-gp inhibitors within 7 days prior to&#xD;
             randomization or anticipated use during the study&#xD;
&#xD;
          -  Inability to swallow capsules, known intolerance to talazoparib and axitinib or its&#xD;
             excipients, known malabsorption syndrome, or other conditions which impair intestinal&#xD;
             absorption.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ritesh Kotecha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ritesh Kotecha, MD</last_name>
    <phone>646-422-4839</phone>
    <email>kotechar@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Voss, MD</last_name>
    <phone>646-888-4721</phone>
    <email>vossm@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Kotecha, MD</last_name>
      <phone>646-422-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Limited Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Kotecha, MD</last_name>
      <phone>646-422-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Kotecha, MD</last_name>
      <phone>646-422-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Kotecha, MD</last_name>
      <phone>646-422-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Limited Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Kotecha, MD</last_name>
      <phone>646-422-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Kotecha, MD</last_name>
      <phone>646-422-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Kotecha, MD</last_name>
      <phone>646-422-4839</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Cancer</keyword>
  <keyword>Advanced Kidney Cancer</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Unresectable Renal Cell Carcinoma</keyword>
  <keyword>Talazoparib</keyword>
  <keyword>Axitinib</keyword>
  <keyword>Metastatic Renal Cell Carcinoma</keyword>
  <keyword>20-001</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

